Skip to main content
NCBI home page
Molecular Medicine logoLink to Molecular Medicine
. 1999 Feb;5(2):86–97.

Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

M Koutsilieris 1, C Reyes-Moreno 1, I Choki 1, A Sourla 1, C Doillon 1, N Pavlidis 1
PMCID: PMC2230409  PMID: 10203574

Abstract

One-third of women with breast cancer will develop bone metastases and eventually die from disease progression at these sites. Therefore, we analyzed the ability of human MG-63 osteoblast-like cells (MG-63 cells), MG-63 conditioned media (MG-63 CM), insulin-like growth factor I (IGF-I), and transforming growth factor beta 1 (TGF-beta1) to alter the effects of adriamycin on cell cycle and apoptosis of estrogen receptor negative (ER-) MDA-MB-231 and positive (ER+) MCF-7 breast cancer cells, using cell count, trypan blue exclusion, flow cytometry, detection of DNA fragmentation by simple agarose gel, and the terminal deoxynucleotidyl transferase (TdT)-mediated nick end-labeling method for apoptosis (TUNEL assay). Adriamycin arrested MCF-7 and MDA-MB-231 cells at G2/M phase in the cell cycle and inhibited cell growth. In addition, adriamycin arrested the MCF-7 cells at G1/G0 phase and induced apoptosis of MDA-MB-231 cells. Exogenous IGF-I partially neutralized the adriamycin cytotoxicity/cytostasis of cancer cells. MG-63 CM and TGF-beta1 partially neutralized the adriamycin cytotoxicity of MDA-MB-231 cells but enhanced adriamycin blockade of MCF-7 cells at G1/G0 phase. MG-63 osteoblast-like cells inhibited growth of MCF-7 cells while promoting growth and rescued MDA-MB-231 cells from adriamycin apoptosis in a collagen co-culture system. These data suggest that osteoblast-derived growth factors can alter the chemotherapy response of breast cancer cells. Conceivably, host tissue (bone)-tumor cell interactions can modify the clinical response to chemotherapy in patients with advanced breast cancer.

Full text

PDF
86

Images in this article

91Fig. 2
on p.91
92Fig. 3
on p.92
93Fig. 4
on p.93
94Fig. 5
on p.94

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 1995 Jan 15;55(2):249–252. [PubMed] [Google Scholar]
  2. Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995 Oct 15;55(20):4633–4639. [PubMed] [Google Scholar]
  3. Boulanger J., Reyes-Moreno C., Koutsilieris M. Mediation of glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 human osteosarcoma cells. Int J Cancer. 1995 May 29;61(5):692–697. doi: 10.1002/ijc.2910610517. [DOI] [PubMed] [Google Scholar]
  4. Coleman R. E., Rubens R. D. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987 Jan;55(1):61–66. doi: 10.1038/bjc.1987.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Doroshow J. H. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun. 1986 Feb 26;135(1):330–335. doi: 10.1016/0006-291x(86)90981-2. [DOI] [PubMed] [Google Scholar]
  6. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I. P., Heber D., Binderup L., Uskokovic M., Koeffler H. P. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res. 1995 Jul 1;55(13):2822–2830. [PubMed] [Google Scholar]
  7. Fornari F. A., Jr, Jarvis W. D., Grant S., Orr M. S., Randolph J. K., White F. K., Mumaw V. R., Lovings E. T., Freeman R. H., Gewirtz D. A. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ. 1994 Jul;5(7):723–733. [PubMed] [Google Scholar]
  8. Fornari F. A., Randolph J. K., Yalowich J. C., Ritke M. K., Gewirtz D. A. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 Apr;45(4):649–656. [PubMed] [Google Scholar]
  9. Gajewski T. F., Thompson C. B. Apoptosis meets signal transduction: elimination of a BAD influence. Cell. 1996 Nov 15;87(4):589–592. doi: 10.1016/s0092-8674(00)81377-x. [DOI] [PubMed] [Google Scholar]
  10. Geier A., Beery R., Haimsohn M., Hemi R., Malik Z., Karasik A. Epidermal growth factor, phorbol esters, and aurintricarboxylic acid are survival factors for MDA-231 cells exposed to adriamycin. In Vitro Cell Dev Biol Anim. 1994 Dec;30A(12):867–874. doi: 10.1007/BF02639397. [DOI] [PubMed] [Google Scholar]
  11. Goldenberg G. J., Wang H., Blair G. W. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res. 1986 Jun;46(6):2978–2983. [PubMed] [Google Scholar]
  12. Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
  13. Janvier R., Sourla A., Koutsilieris M., Doillon C. J. Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res. 1997 May-Jun;17(3A):1551–1557. [PubMed] [Google Scholar]
  14. Koenders P. G., Beex L. V., Langens R., Kloppenborg P. W., Smals A. G., Benraad T. J. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat. 1991 Mar;18(1):27–32. doi: 10.1007/BF01975440. [DOI] [PubMed] [Google Scholar]
  15. Koutsilieris M., Frenette G., Lazure C., Lehoux J. G., Govindan M. V., Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. 1993 Mar-Apr;13(2):481–486. [PubMed] [Google Scholar]
  16. Koutsilieris M., Polychronakos C. Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res. 1992 May-Jun;12(3):905–910. [PubMed] [Google Scholar]
  17. Koutsilieris M., Reyes-Moreno C., Sourla A., Dimitriadou V., Choki I. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res. 1997 May-Jun;17(3A):1461–1465. [PubMed] [Google Scholar]
  18. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol. 1995 Jan;18(1):51–64. doi: 10.1016/1040-8428(94)00122-a. [DOI] [PubMed] [Google Scholar]
  19. Koutsilieris M., Sourla A., Pelletier G., Doillon C. J. Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. J Bone Miner Res. 1994 Nov;9(11):1823–1832. doi: 10.1002/jbmr.5650091120. [DOI] [PubMed] [Google Scholar]
  20. Kyprianou N., English H. F., Davidson N. E., Isaacs J. T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 1991 Jan 1;51(1):162–166. [PubMed] [Google Scholar]
  21. Oh Y., Müller H. L., Ng L., Rosenfeld R. G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem. 1995 Jun 9;270(23):13589–13592. doi: 10.1074/jbc.270.23.13589. [DOI] [PubMed] [Google Scholar]
  22. Oltvai Z. N., Korsmeyer S. J. Checkpoints of dueling dimers foil death wishes. Cell. 1994 Oct 21;79(2):189–192. doi: 10.1016/0092-8674(94)90188-0. [DOI] [PubMed] [Google Scholar]
  23. Perry R. R., Kang Y., Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol. 1995 May;2(3):238–245. doi: 10.1007/BF02307030. [DOI] [PubMed] [Google Scholar]
  24. Párrizas M., LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology. 1997 Mar;138(3):1355–1358. doi: 10.1210/endo.138.3.5103. [DOI] [PubMed] [Google Scholar]
  25. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H. L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995 Jun 1;55(11):2463–2469. [PubMed] [Google Scholar]
  26. Resnicoff M., Burgaud J. L., Rotman H. L., Abraham D., Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res. 1995 Sep 1;55(17):3739–3741. [PubMed] [Google Scholar]
  27. Reyes-Moreno C., Sourla A., Choki I., Doillon C., Koutsilieris M. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology. 1998 Aug;52(2):341–347. doi: 10.1016/s0090-4295(98)00182-4. [DOI] [PubMed] [Google Scholar]
  28. Sell C., Baserga R., Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 1995 Jan 15;55(2):303–306. [PubMed] [Google Scholar]
  29. Sherry M. M., Greco F. A., Johnson D. H., Hainsworth J. D. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med. 1986 Sep;81(3):381–386. doi: 10.1016/0002-9343(86)90286-x. [DOI] [PubMed] [Google Scholar]
  30. Siwek B., Lacroix M., De Pollak C., Marie P., Body J. J. Secretory products of breast cancer cells specifically affect human osteoblastic cells: partial characterization of active factors. J Bone Miner Res. 1997 Apr;12(4):552–560. doi: 10.1359/jbmr.1997.12.4.552. [DOI] [PubMed] [Google Scholar]
  31. Sourla A., Doillon C., Koutsilieris M. Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells. Anticancer Res. 1996 Sep-Oct;16(5A):2773–2780. [PubMed] [Google Scholar]
  32. Teixeira C., Reed J. C., Pratt M. A. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995 Sep 1;55(17):3902–3907. [PubMed] [Google Scholar]
  33. Theriault R. L., Hortobagyi G. N. Bone metastasis in breast cancer. Anticancer Drugs. 1992 Oct;3(5):455–462. doi: 10.1097/00001813-199210000-00002. [DOI] [PubMed] [Google Scholar]
  34. Vandewalle B., Hornez L., Wattez N., Revillion F., Lefebvre J. Vitamin-D3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer. 1995 Jun 9;61(6):806–811. doi: 10.1002/ijc.2910610611. [DOI] [PubMed] [Google Scholar]
  35. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell. 1996 Nov 15;87(4):619–628. doi: 10.1016/s0092-8674(00)81382-3. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES